Diluent-vial (Diluent Vial)
Temsirolimus Kit
Product Images NDC 72611-785
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Temsirolimus (NDC 72611-785). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Almaject, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-1 (Figure 1)
The text provides a graph showing the Kaplan-Meier curves for overall survival when using Temsirolimus versus Interferon treatment. The x-axis represents the months to death from randomization, with values ranging from 0 to 25. The treatment options are represented by the labels "Temsirolimus" and "IFN." The graph shows the Survival Distribution function up to 30 months, but there is no additional text to provide further context or explanation.*
Kit-carton (Kit Carton)
This is a product description of Temsirolimus Injection manufactured by Gland Pharma Limited in India, distributed by Almaject Inc. in the USA. The injection comes in a single-dose vial with 25mg/mL of Temsirolimus, requiring two dilutions before administration, and must be refrigerated at 2° to 8°C. The package also includes a single-dose vial of diluent for Temsirolimus Injection. The package insert contains dilution instructions and recommended dosage. Rx only. NDC 72611-785-02.*
Structure (Structure)
Temsirolimus-concentrate-vial (Temsirolimus Concentrate Vial)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
